Cancer Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Extensive research associated with cancer treatment in western countries
- Growing investment in the development of advanced therapies
Challenges
- Expensive Cancer Treatment Therapies
- Lack of Awareness About the Disease in Low and Middle-Income Economic Regions
Cancer Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
11.2% |
|
Base Year Market Size (2024) |
USD 187.33 billion |
|
Forecast Year Market Size (2037) |
USD 744.68 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cancer drugs is estimated at USD 205.16 billion.
Cancer Drugs Market size was valued at USD 187.33 billion in 2024 and is likely to cross USD 744.68 billion by 2037, expanding at more than 11.2% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is estimated to dominate majority revenue share by 2037, owing to increasing awareness, rise in disposable incomes, high incidence rate of cancer, and need to develop innovative cancer treatment solutions in the region.
The major players in the market are F. Hoffman-La Roche Ltd, Celgene Corp, Novartis AG, Pfizer Inc, Johnson and Johnson, among others.
